Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon T McInnes

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Lancet (London, England)|April 11, 2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Diabetes Care|April 28, 2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter S Sever, Neil R Poulter, Björn Dahlöf, et al.
Journal of Hypertension|October 16, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetesJan Ostergren, Neil R Poulter, Peter S Sever, et al.
Lancet (London, England)|September 13, 2005
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Peter S Sever, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
Hypertension (Dallas, Tex. : 1979)|July 18, 2012
Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adultsLaura Paul, Panniyammakal Jeemon, Jonathan Hewitt, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
Lancet (London, England)|June 23, 2004
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|August 21, 2013
Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertensionClaire E Hastie, Panniyammakal Jeemon, Holli Coleman, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Lancet (London, England)|April 11, 2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.
Diabetes Care|April 28, 2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter S Sever, Neil R Poulter, Björn Dahlöf, et al.
Journal of Hypertension|October 16, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetesJan Ostergren, Neil R Poulter, Peter S Sever, et al.
Lancet (London, England)|September 13, 2005
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Peter S Sever, Neil R Poulter, et al.
Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.
Hypertension (Dallas, Tex. : 1979)|July 18, 2012
Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adultsLaura Paul, Panniyammakal Jeemon, Jonathan Hewitt, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
Lancet (London, England)|June 23, 2004
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialMichael A Weber, Stevo Julius, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|August 21, 2013
Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertensionClaire E Hastie, Panniyammakal Jeemon, Holli Coleman, et al.
Pageof 6